The Trump administration looks set to unveil a new slate of most favored nation (MFN) drug pricing deals with several mid-sized biopharma companies, according to Bloomberg. | The Trump administration will soon unveil most favored nation drug pricing deals with several mid-sized biopharma companies, according to a report from Bloomberg. The announcement is expected on Monday.

The companies would agree to align prices on outpatient drugs for state Medicaid programs with what they charge in foreign countries

The Trump administration is expected to announce voluntary drug-pricing agreements with midsize biotech companies, requiring discounts for outpatient medicines supplied through…